Medtronic plc. (MDT) key performance indicators and operating metrics (84 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Organic revenue growth | 13.70 percent | FY2027-Q1 |
| Medical Surgical portfolio organic revenue growth | 10.20 percent | FY2027-Q1 |
| Cardiovascular portfolio organic revenue growth | 18.90 percent | FY2027-Q1 |
| Neuroscience portfolio organic revenue growth | 9.30 percent | FY2027-Q1 |
| Cardiac Ablation Solutions revenue growth | 88.00 percent | FY2027-Q1 |
| Revenue growth as reported | 9.90 percent | FY2026-Q4 |
| Cardiovascular revenue | 3.93B | FY2027-Q1 |
| Medical Surgical revenue | 2.28B | FY2027-Q1 |
| Neuroscience revenue | 2.68B | FY2027-Q1 |
| Diabetes revenue | 843M | FY2027-Q1 |
| Adjusted diluted earnings per share | 1.45 USD_per_share | FY2027-Q1 |
| Adjusted operating margin | 23.70 percent | FY2027-Q1 |
| Non-GAAP operating profit | 2.32B | FY2027-Q1 |
| Diabetes organic revenue growth | 8.30 percent | FY2026-Q3 |
Back to MDT overview · MDT earnings · MDT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.